Cantex Pharmaceuticals has commenced an investigator-initiated Phase II clinical trial evaluating azeliragon capsule together with stereotactic radiosurgery in brain metastases patients.

The study is designed to determine whether the combined therapy can eliminate the use of dexamethasone for controlling swelling in the brain.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Safety and effectiveness of the combined therapy will also be evaluated in the study.

Cantex CEO Stephen Marcus said: “We are very excited to initiate enrolment into this important clinical trial.

“With the initiation of this Phase II clinical trial, Cantex expands the cancer indications for which azeliragon is being investigated, which now include active Phase II clinical trials in glioblastoma, breast cancer, pancreatic cancer, and a Phase II/III clinical trial in hospitalised Covid-19 patients to prevent acute kidney injury, accelerating azeliragon’s development as a treatment of very aggressive and difficult to treat cancers and other illnesses.”

Azeliragon blocks the interaction of S100A9 protein with receptor for advanced glycation end products (RAGE) thereby restoring sensitivity to radiation therapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It was discovered by vTv Therapeutics and is originally under development for Alzheimer’s disease. Cantex licensed global rights to azeliragon.

Recently, vTv Therapeutics announced plans to commence a Phase III clinical trial of cadisegliatin for treating type 1 diabetes.

Cadisegliatin, a liver-selective glucokinase activator, is indicated as an adjunct therapy along with insulin for reducing the number of hypoglycaemic events.

vTv also plans to expand the drug indications in treating type 2 diabetes, glioblastoma, primary mitochondrial myopathy, chronic obstructive pulmonary and renal diseases.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact